Company intelligence / Profile preview

Locate Bio

Nottingham, United Kingdomlocatebio.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

Locate Bio’s lead product LDGraft™, a recombinant human BMP‑2 bone graft with advanced drug delivery/scaffold technology, is in clinical trials for lumbar interbody fusion and has received FDA Breakthrough Device designation. Other pipeline programs are at the preclinical stage or discontinued. No published pivotal clinical results yet.

Therapeutic areas: NeurologyInfectious DiseasesRheumatology
Modalities: Recombinant protein (rhBMP‑2)Synthetic biomaterial (calcium phosphate)Cell therapy (preclinical programs)Device (tissue scaffold/drug delivery)
Industry: Biotech

Drug pipeline

2 assets

LDGraft

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Not specified in public sources.

Beyond the preview

Go deeper on Locate Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Locate Bio.

Explore the full profile